Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF): Price and Financial Metrics
GET POWR RATINGS... FREE!
CANF POWR Grades
- Growth is the dimension where CANF ranks best; there it ranks ahead of 94.22% of US stocks.
- The strongest trend for CANF is in Momentum, which has been heading down over the past 31 weeks.
- CANF ranks lowest in Momentum; there it ranks in the 11th percentile.
CANF Stock Summary
- For CANF, its debt to operating expenses ratio is greater than that reported by just 4.73% of US equities we're observing.
- CANF's price/sales ratio is 629.1; that's higher than the P/S ratio of 98.84% of US stocks.
- Revenue growth over the past 12 months for Can-Fite BioPharma Ltd comes in at -80.03%, a number that bests merely 2.41% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Can-Fite BioPharma Ltd are ONTX, IMV, CLDX, RFL, and DZSI.
- CANF's SEC filings can be seen here. And to visit Can-Fite BioPharma Ltd's official web site, go to www.canfite.com.
CANF Valuation Summary
- In comparison to the median Healthcare stock, CANF's EV/EBIT ratio is 230.34% lower, now standing at -34.8.
- CANF's price/sales ratio has moved NA NA over the prior 89 months.
- CANF's price/sales ratio has moved NA NA over the prior 89 months.
Below are key valuation metrics over time for CANF.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CANF | 2018-08-08 | 25.6 | 7.1 | -4.3 | -4.7 |
| CANF | 2017-03-27 | 149.4 | 2.4 | -4.9 | -1.7 |
| CANF | 2016-04-13 | 252.3 | 4.0 | -8.2 | -5.5 |
| CANF | 2016-04-12 | 249.4 | 4.0 | -8.1 | -5.4 |
| CANF | 2016-01-11 | NA | 3.8 | -3.9 | -2.5 |
| CANF | 2015-01-14 | NA | 6.9 | -3.5 | -2.8 |
CANF Growth Metrics
- Its 3 year revenue growth rate is now at 1054.28%.
- Its 4 year cash and equivalents growth rate is now at -1.86%.
- Its 5 year net income to common stockholders growth rate is now at -170.57%.
The table below shows CANF's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2020-12-31 | 0.763 | -12.063 | -14.443 |
| 2019-12-31 | 2.032 | -10.8 | -9.587 |
| 2018-12-31 | 3.82 | -4.155 | -6.571 |
| 2018-12-31 | 3.82 | -4.155 | -6.571 |
| 2018-12-31 | 3.82 | -4.155 | -6.571 |
| 2017-12-31 | 0.79272 | -8.93673 | -4.67397 |
CANF Stock Price Chart Interactive Chart >
CANF Price/Volume Stats
| Current price | $2.09 | 52-week high | $4.39 |
| Prev. close | $2.00 | 52-week low | $1.51 |
| Day low | $2.04 | Volume | 75,300 |
| Day high | $2.10 | Avg. volume | 1,957,034 |
| 50-day MA | $2.20 | Dividend yield | N/A |
| 200-day MA | $2.09 | Market Cap | 35.93M |
Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF) Company Bio
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.
Latest CANF News From Around the Web
Below are the latest news stories about Can-Fite BioPharma Ltd that investors may wish to consider to help them evaluate CANF as an investment opportunity.
Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer StudyPETACH TIKVA, Israel, July 08, 2021--Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study |
Can-Fite BioPharma Signs Deal With Vetbiolix For Development Of Piclidenoson For Pets(RTTNews) - Can-Fite BioPharma Ltd. (CANF) said it has reached a development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats. Vetbiolix will have the exclusive right to Piclidenoson in |
Can-Fite Stock Gains On Piclidenoson Development Pact For PetsCan-Fite BioPharma Ltd (NYSE: CANF) has signed a development and commercialization agreement with France-based veterinary biotech company, Vetbiolix, to develop Piclidenoson to treat osteoarthritis in companion animals. Vetbiolix will have the exclusive right to Piclidenoson in the veterinary osteoarthritis market for two years, during which it will conduct proof-of-concept studies and cover all associated costs. Suppose the studies yield positive data, and Vetbiolix exercises its option to obta |
Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for PetsPETACH TIKVA, Israel, June 28, 2021--Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets |
Can-Fite Receives Notice of Patent Allowance in China for NASH TreatmentPETACH TIKVA, Israel, Jun 16, 2021--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the Chinese National Intellectual Property Administration has issued a Notice of Allowance for its patent titled "An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation". This patent addresses the use of the A3 Adenosine Receptor (A |
CANF Price Returns
| 1-mo | -7.93% |
| 3-mo | -2.79% |
| 6-mo | -0.48% |
| 1-year | -13.28% |
| 3-year | -88.09% |
| 5-year | -93.43% |
| YTD | 17.42% |
| 2020 | -46.06% |
| 2019 | -82.54% |
| 2018 | -14.86% |
| 2017 | -37.82% |
| 2016 | -18.49% |
Continue Researching CANF
Want to see what other sources are saying about Can-Fite BioPharma Ltd's financials and stock price? Try the links below:Can-Fite BioPharma Ltd (CANF) Stock Price | Nasdaq
Can-Fite BioPharma Ltd (CANF) Stock Quote, History and News - Yahoo Finance
Can-Fite BioPharma Ltd (CANF) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...